

DAFTAR PUSTAKA

- Almagro, P., 2019. Inhaled corticosteroids and pneumonia mortality in COPD patients.
- Almirall, J., Serra-Prat, M., Bolibar, I., dan Balasso, V., 2017. Risk Factors for Community-Acquired Pneumonia in Adults: A Systematic Review of Observational Studies. *Respiration*, 94: 299–311.
- Ashdown, H.F., Smith, M., McFadden, E., Pavord, I.D., Butler, C.C., dan Bafadhel, M., 2022. Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population. *ERJ Open Research*, 8: 00606–02021.
- Barnes, P.J., 2006. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. *British Journal of Pharmacology*, 148: 245–254.
- Baskaran, V., Murray, R.L., Hunter, A., Lim, W.S., dan McKeever, T.M., 2019. Effect of tobacco smoking on the risk of developing community acquired pneumonia: A systematic review and meta-analysis. *PLOS ONE*, 14: e0220204.
- Battaglia, S., Cardillo, I., Lavorini, F., Spatafora, M., dan Scichilone, N., 2014. Safety Considerations of Inhaled Corticosteroids in the Elderly. *Drugs & Aging*, 31: 787–796.
- Battaglia, S., Cardillo, I., Lavorini, F., Spatafora, M., dan Scichilone, N., 2015. Erratum to: Safety Considerations of Inhaled Corticosteroids in the Elderly. *Drugs & Aging*, 32: 1067–1076.
- Brown, J.D., Harnett, J., Chambers, R., dan Sato, R., 2018. The relative burden of community-acquired pneumonia hospitalizations in older adults: a retrospective observational study in the United States. *BMC Geriatrics*, 18: 92.
- Brunetti, V.C., Ayele, H.T., Yu, O.H.Y., Ernst, P., dan Fillion, K.B., 2021. Type 2 diabetes mellitus and risk of community-acquired pneumonia: a systematic review and meta-analysis of observational studies. *CMAJ Open*, 9: E62–E70.
- Calverley, P.M.A., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W., dkk., 2007. Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. *New England Journal of Medicine*, 356: 775–789.
- Cascini, S., Kirchmayer, U., Belleudi, V., Bauleo, L., Pistelli, R., Di Martino, M., dkk., 2017. Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease and Risk of Pneumonia: A Nested Case-Control Population-based Study in Lazio (Italy)—The OUTPUT Study. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 14: 311–317.
- Chen, H., Sun, J., Huang, Q., Liu, Y., Yuan, M., Ma, C., dkk., 2021. Inhaled Corticosteroids and the Pneumonia Risk in Patients With Chronic Obstructive

Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials. *Frontiers in Pharmacology*, 12: 691621.

- Cheng, S.-L., Su, K.-C., Wang, H.-C., Yang, P.-C., dan Perng, S.D.-W., 2014. Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia. *Drug Design, Development and Therapy*, 601.
- Chou, C.-C., Shen, C.-F., Chen, S.-J., Chen, H.-M., Wang, Y.-C., Chang, W.-S., dkk., 2019. Recommendations and guidelines for the treatment of pneumonia in Taiwan. *Journal of Microbiology, Immunology and Infection*, 52: 172–199.
- Chou, C.-Y., Wang, S.-M., Liang, C.-C., Chang, C.-T., Liu, J.-H., Wang, I.-K., dkk., 2014. Risk of Pneumonia Among Patients With Chronic Kidney Disease in Outpatient and Inpatient Settings. *Medicine*, 93: e174.
- DiPiro, J.T. (Editor), 2020. *Pharmacotherapy: A Pathophysiologic Approach*, Eleventh edition. ed. McGraw Hill Medical, New York.
- DiSantostefano, R.L., Sampson, T., Van Le, H., Hinds, D., Davis, K.J., dan Bakerly, N.D., 2014. Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: A new-user cohort study. *PLoS ONE*, 9: .
- Domachowske, J. dan Suryadevara, M., 2020. *Clinical Infectious Diseases Study Guide: A Problem-Based Approach*. Springer International Publishing, Cham.
- Ferguson, G.T., Tashkin, D.P., Skärby, T., Jorup, C., Sandin, K., Greenwood, M., dkk., 2017. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. *Respiratory Medicine*, 132: 31–41.
- Ferreira-Coimbra, J., Sarda, C., dan Rello, J., 2020. Burden of Community-Acquired Pneumonia and Unmet Clinical Needs. *Advances in Therapy*, 37: 1302–1318.
- Festic, E., Bansal, V., Gupta, E., dan Scanlon, P.D., 2016. Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic Review and Meta-Analysis. *COPD*, 13: 312–326.
- Festic, E. dan Scanlon, P.D., 2015. Incident Pneumonia and Mortality in Patients with Chronic Obstructive Pulmonary Disease. A Double Effect of Inhaled Corticosteroids? *American Journal of Respiratory and Critical Care Medicine*, 191: 141–148.
- Ghia, C.J. dan Rambhad, G.S., 2022. Systematic review and meta-analysis of comorbidities and associated risk factors in Indian patients of community-acquired pneumonia. *SAGE Open Medicine*, 10: 205031212210954.

GOLD, 2022. Global Strategy For The Diagnosis, Management, And Prevention of Chronic Obstructive Pulmonary Disease (2022 Report).

Hirano, Ryosuke, Fujita, M., Matsumoto, T., On, R., dan Watanabe, K., 2018. Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan. *International Journal of Chronic Obstructive Pulmonary Disease*, Volume 13: 3503–3509.

Hirano, R., Fujita, M., Matsumoto, T., On, R., dan Watanabe, K., 2018. Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan. *International Journal of COPD*, 13: 3503–3509.

Jameson, J.L., Kasper, D.L., Longo, D.L., Fauci, A.S., Hauser, S.L., dan Loscalzo, J. (Editor), 2018. *Harrison's Principle of Internal Edition*, 20th Ed. ed. McGraw-Hill Education, United States.

Janson, C., Johansson, G., Ställberg, B., Lisspers, K., Olsson, P., Keininger, D.L., dkk., 2018. Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational study. *Respiratory Research*, 19: 172.

Janson, C., Larsson, K., Lisspers, K.H., Stallberg, B., Stratelis, G., Goike, H., dkk., 2013. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting 2 agonist: observational matched cohort study (PATHOS). *BMJ*, 346: f3306–f3306.

Janson, C., Stratelis, G., Miller-Larsson, A., Harrison, T., dan Larsson, K., 2017a. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. *International Journal of Chronic Obstructive Pulmonary Disease*, Volume 12: 3055–3064.

Janson, C., Stratelis, G., Miller-Larsson, A., Harrison, T.W., dan Larsson, K., 2017b. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. *International Journal of Chronic Obstructive Pulmonary Disease*, 12: 3055–3064.

Kemenkes RI, 2013. Riset Kesehatan Dasar Tahun 2013.

Kemenkes RI, 2019. Profil Kesehatan Indonesia Tahun 2018.

Kern, D.M., Davis, J., Williams, S.A., Tunceli, O., Wu, B., Hollis, S., dkk., 2015. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study. *Respiratory Research*, 16: 52.

Koehorst-ter Huurne, K., Groothuis-Oudshoorn, C.G., vanderValk, P.D., Movig, K.L., van der Palen, J., dan Brusse-Keizer, M., 2018. Association between poor therapy adherence to inhaled corticosteroids and tiotropium and

morbidity and mortality in patients with COPD. *International Journal of Chronic Obstructive Pulmonary Disease*, 13: 1683–1690.

Lee, E.G., Kim, Y., Hwang, Y.I., Yoo, K.H., Lee, S.E., Jung, K.Y., dkk., 2023. Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD. *Scientific Reports*, 13: .

Lee, Ji-Ho, Park, Y.H., Kang, D.R., Lee, S.J., Lee, M.K., Kim, S.-H., dkk., 2020. Risk of Pneumonia Associated with Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease: A Korean Population-Based Study. *International Journal of Chronic Obstructive Pulmonary Disease*, Volume 15: 3397–3406.

Lee, J.-H., Park, Y.H., Kang, D.R., Lee, S.J., Lee, M.K., Kim, S.-H., dkk., 2020. Risk of pneumonia associated with inhaled corticosteroid in patients with chronic obstructive pulmonary disease: A Korean population-based study. *International Journal of COPD*, 15: 3397–3406.

Leitao Filho, F.S., Takiguchi, H., Akata, K., Ra, S.W., Moon, J.-Y., Kim, H.K., dkk., 2021. Effects of Inhaled Corticosteroid/Long-Acting β_2 -Agonist Combination on the Airway Microbiome of Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Clinical Trial (DISARM). *American Journal of Respiratory and Critical Care Medicine*, 204: 1143–1152.

Lemeshow, S. dan World Health Organization (Editor), 1990. *Adequacy of Sample Size in Health Studies*. Published on behalf of the World Health Organization by Wiley ; Distributed in the U.S.A., Canada, and Japan by Liss, Chichester [England] ; New York : New York, NY, USA.

Lemke, T.L., Williams, D.A., Roche, V.F., dan Zito, S.W. (Editor), 2013. *Foye's Principles of Medicinal Chemistry*, Seventh Edition. ed. Lippincott Williams & Wilkins, Philadelphia.

Lipson, D.A., Barnhart, F., Brealey, N., Brooks, J., Criner, G.J., Day, N.C., dkk., 2018. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. *New England Journal of Medicine*, 378: 1671–1680.

Lodise, T.P., Li, J., Gandhi, H.N., O'Brien, G., dan Sethi, S., 2020. Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies. *International Journal of Chronic Obstructive Pulmonary Disease*, Volume 15: 2889–2900.

Malerba, M., Foci, V., Patrucco, F., Pochetti, P., Nardin, M., Pelaia, C., dkk., 2019. Single Inhaler LABA/LAMA for COPD. *Frontiers in Pharmacology*, 10: 390.

- Martinez, F.J., Boscia, J., Feldman, G., Scott-Wilson, C., Kilbride, S., Fabbri, L., dkk., 2013. Fluticasone furoate/vilanterol (100/25; 200/25 µg) improves lung function in COPD: A randomised trial. *Respiratory Medicine*, 107: 550–559.
- Martinez-Garcia, M.A., Faner, R., Oscullo, G., de la Rosa, D., Soler-Cataluña, J.-J., Ballester, M., dkk., 2020. Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis. *American Journal of Respiratory and Critical Care Medicine*, 201: 1078–1085.
- Mathioudakis, A.G., Janssens, W., Sivapalan, P., Singanayagam, A., Dransfield, M.T., Jensen, J.-U.S., dkk., 2020. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. *Thorax*, 75: 520–527.
- McInerny, T.K. (Editor), 2017. *American Academy of Pediatrics Textbook of Pediatric Care*, 2nd edition. ed. American Academy of Pediatrics, Elk Grove Village, IL.
- McLaughlin, J.M., Khan, F.L., Thoburn, E.A., Isturiz, R.E., dan Swerdlow, D.L., 2020. Rates of hospitalization for community-acquired pneumonia among US adults: A systematic review. *Vaccine*, 38: 741–751.
- Miravittles, M., Auladell-Rispau, A., Monteagudo, M., Vázquez-Niebla, J.C., Mohammed, J., Nuñez, A., dkk., 2021. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. *European Respiratory Review*, 30: 210075.
- Morjaria, J.B., Rigby, A., dan Morice, A.H., 2017. Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study. *Lung*, 195: 281–288.
- Nannini, L.J., Poole, P., Milan, S.J., dan Kesterton, A., 2013. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. *The Cochrane Database of Systematic Reviews*, 2013: CD006826.
- Ohar, J.A., Crater, G.D., Emmett, A., Ferro, T.J., Morris, A.N., Raphiou, I., dkk., 2014. Fluticasone propionate/salmeterol 250/50 µg versus salmeterol 50 µg after chronic obstructive pulmonary disease exacerbation. *Respiratory Research*, 15: .
- Olson, G. dan Davis, A.M., 2020. Diagnosis and Treatment of Adults With Community-Acquired Pneumonia. *JAMA*, 323: 885.
- Papadakis, M.A., McPhee, S.J., dan Rabow, M.W. (Editor), 2021. *Current Medical Diagnosis & Treatment*, Sixtieth Edition. ed. McGraw Hill, United States.
- Park, J.W., Hong, Y., Jung, K.-S., Rhee, C.K., Park, J.H., Choi, H.S., dkk., 2023. The Impact of Inhaled Corticosteroids on the Prognosis of Chronic

Obstructive Pulmonary Disease. *International Journal of COPD*, 18: 733–743.

Peate, I. (Editor), 2018. *Fundamentals of Applied Pathophysiology: An Essential Guide For Nursing and Healthcare Students*, Third edition. ed. Wiley, Hoboken, NJ.

Perhimpunan Dokter Paru Indonesia, 2003. *Pedoman Diagnosis & Penatalaksanaan di Indonesia : Pneumonia Komuniti*. Indonesia.

Ralston, S.H., Penman, I.D., Strachan, M.W.J., dan Hobson, R.P. (Editor), 2022. *Davidson's Principles and Practice of Medicine*, 24th edition. ed. Churchill Livingstone/Elsevier, Edinburgh.

Ramirez, J.A., Wiemken, T.L., Peyrani, P., Arnold, F.W., Kelley, R., Mattingly, W.A., dkk., 2017. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. *Clinical Infectious Diseases*, 65: 1806–1812.

Rivero-Calle, I., Pardo-Seco, J., Aldaz, P., Vargas, D.A., Mascarós, E., Redondo, E., dkk., 2016. Incidence and risk factor prevalence of community-acquired pneumonia in adults in primary care in Spain (NEUMO-ES-RISK project). *BMC Infectious Diseases*, 16: 645.

Rossi, A., Van Der Molen, T., Del Olmo, R., Papi, A., Wehbe, L., Quinn, M., dkk., 2014. INSTEAD: A randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. *European Respiratory Journal*, 44: 1548–1556.

Ruby, D., 2020. The Impact of Community-acquired Pneumonia on Acute Exacerbation of Chronic Obstructive Pulmonary Disease Patients as Regards In-hospital Complications and Early Readmission. *The Open Respiratory Medicine Journal*, 14: 10–15.

Safiri, S., Carson-Chahhoud, K., Noori, M., Nejadghaderi, S.A., Sullman, M.J.M., Ahmadian Heris, J., dkk., 2022. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019. *BMJ*, e069679.

Sharafkhaneh, A., Southard, J.G., Goldman, M., Uryniak, T., dan Martin, U.J., 2012. Effect of budesonide/formoterol pMDI on COPD exacerbations: A double-blind, randomized study. *Respiratory Medicine*, 106: 257–268.

Sibila, O., Soto-Gomez, N., dan Restrepo, M.I., 2015. The risk and outcomes of pneumonia in patients on inhaled corticosteroids. *Pulmonary Pharmacology & Therapeutics*, 32: 130–136.

Sivapalan, P., Ingebrigtsen, T.S., Rasmussen, D.B., Sørensen, R., Rasmussen, C.M., Jensen, C.B., dkk., 2019. COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia:

- nationwide data on 67 000 patients with COPD followed for 12 months. *BMJ Open Respiratory Research*, 6: e000407.
- Su, Y.-C., Jalalvand, F., Thegerström, J., dan Riesbeck, K., 2018. The Interplay Between Immune Response and Bacterial Infection in COPD: Focus Upon Non-typeable *Haemophilus influenzae*. *Frontiers in Immunology*, 9: 2530.
- Suissa, S., Patenaude, V., Lapi, F., dan Ernst, P., 2013. Inhaled corticosteroids in COPD and the risk of serious pneumonia. *Thorax*, 68: 1029–1036.
- Tamondong-Lachica, D.R., Skolnik, N., Hurst, J.R., Marchetti, N., Rabe, A.P.J., Montes de Oca, M., dkk., 2023. GOLD 2023 Update: Implications for Clinical Practice. *International Journal of Chronic Obstructive Pulmonary Disease*, 18: 745–754.
- Tashkin, D.P., Miravittles, M., Celli, B.R., Metzdorf, N., Mueller, A., Halpin, D.M.G., dkk., 2018. Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial. *Respiratory Research*, 19: 196.
- Torres, A., Niederman, M.S., Chastre, J., Ewig, S., Fernandez-Vandellos, P., Hanberger, H., dkk., 2017. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). *European Respiratory Journal*, 50: 1700582.
- Torres, A., Peetermans, W.E., Viegi, G., dan Blasi, F., 2013. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. *Thorax*, 68: 1057–1065.
- Vos, T., Lim, S.S., Abbafati, C., Abbas, K.M., Abbasi, M., Abbasifard, M., dkk., 2020. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*, 396: 1204–1222.
- Wang, C.-Y., Lai, C.-C., Yang, W.-C., Lin, C.-C., Chen, L., Wang, H.-C., dkk., 2016. The association between inhaled corticosteroid and pneumonia in COPD patients: The improvement of patients' life quality with COPD in Taiwan (IMPACT) study. *International Journal of COPD*, 11: 2775–2783.
- Wedzicha, J.A., Banerji, D., Chapman, K.R., Vestbo, J., Roche, N., Ayers, R.T., dkk., 2016. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. *New England Journal of Medicine*, 374: 2222–2234.
- Wedzicha, J.A., Zhong, N., Ichinose, M., Humphries, M., Fogel, R., Thach, C., dkk., 2017. Indacaterol/glycopyrronium versus salmeterol/fluticasone in

- Asian patients with COPD at a high risk of exacerbations: Results from the FLAME study. *International Journal of COPD*, 12: 339–349.
- Williams, D.M., 2018. Clinical Pharmacology of Corticosteroids. *Respiratory Care*, 63: 655–670.
- Wing, E.J. dan Schiffman, F.J. (Editor), 2020. *Cecil Essetials Of Medicine*, 10th Ed. ed. Elsevier, Philadelphia.
- World Health Organization [WHO], 2020. 'The Top 10 Causes of Death', .
- Xu, H., Gasparini, A., Ishigami, J., Mzayen, K., Su, G., Barany, P., dkk., 2017. eGFR and the Risk of Community-Acquired Infections. *Clinical Journal of the American Society of Nephrology*, 12: 1399.
- Yang, I.A., Clarke, M.S., Sim, E.H., dan Fong, K.M., 2012. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*, 2016: .
- Yang, M., Chen, H., Zhang, Y., Du, Y., Xu, Y., Jiang, P., dkk., 2017. Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis. *Inhalation Toxicology*, 29: 219–226.
- Yawn, Barbara P, Li, Y., Tian, H., Zhang, J., Arcona, S., dan Kahler, K.H., 2013. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. *International Journal of Chronic Obstructive Pulmonary Disease*, 8: 295–304.
- Yawn, B.P., Li, Y., Tian, H., Zhang, J., Arcona, S., dan Kahler, K.H., 2013. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: A retrospective claims data analysis. *International Journal of COPD*, 8: 295–304.
- Yulianti, E., 2022. 'Pengaruh Pemberian Inhalasi Budesonid 160 mcg/Formoterol Fumarat 4,5 mcg Turbuhaler Dibandingkan Dengan Flutikason Propionat 250 mcg/salmeterol Xinafoat 50 mcg diskus Pada Rehospitalisasi Pasien PPOK (Penyakit Paru Obstruktif Kronik) Setelah Rawat Inap di Rumah Sakit Paru Respira', . Universitas Gadjah Mada, Yogyakarta.
- Zeind, C.S. dan Carvalho, M.G. (Editor), 2018. *Applied Therapeutics: The Clinical Use of Drugs*, Eleventh edition. ed. Wolters Kluwer Health, Place of publication not identified.
- Zekavat, S.M., Honigberg, M., Pirruccello, J.P., Kohli, P., Karlson, E.W., Newton-Cheh, C., dkk., 2021. Elevated Blood Pressure Increases Pneumonia Risk: Epidemiological Association and Mendelian Randomization in the UK Biobank. *Med*, 2: 137-148.e4.